Latexin inhibits the proliferation of CD133+ miapaca-2 pancreatic cancer stem-like cells

World Journal of Surgical Oncology

Volumn 12, Issue 1, 2014, Pages

  Xue, Zhan Xiong ^a   Zheng, Ji Hang ^a   Zheng, Zhi Qiang ^a   Cai, Jing Li ^a   Ye, Xiao Hua ^b   Wang, Cheng ^a   Sun, Wei Jian ^a   Zhou, Xiang ^a   Lu, Ming Dong ^a   Li, Pi Hong ^a   Cai, Zhen Zhai ^a  

^a THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b ZHEJIANG NORMAL UNIVERSITY   (China)

Author keywords

Bax; Bcl 2; c myc; Cancer stem cell; CD133; Latexin; Pancreatic cancer

Indexed keywords

CD133 ANTIGEN; LATEXIN; MESSENGER RNA; MYC PROTEIN; PROTEIN BAX; PROTEIN BCL 2; REGULATOR PROTEIN; UNCLASSIFIED DRUG; ANTIGEN; GLYCOPROTEIN; LATEXIN PROTEIN, RAT; LEUKOCYTE ANTIGEN; PEPTIDE; PROM1 PROTEIN, HUMAN; PROM1 PROTEIN, MOUSE; PROM1 PROTEIN, RAT; RNA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER STEM CELL; CARCINOGENICITY; CARCINOMA CELL LINE; CELL COUNTING; CELL COUNTING KIT 8; CELL ISOLATION; CELL PROLIFERATION; CELL SELECTION; CONTROLLED STUDY; CULTURE MEDIUM; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INVESTIGATIVE PROCEDURES; MALE; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PANCREATIC CANCER CELL LINE; PROTEIN EXPRESSION; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; DRUG SCREENING; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUDE MOUSE; PANCREAS TUMOR; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

AC133 ANTIGEN; ANIMALS; ANTIGENS; ANTIGENS, CD; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS; PEPTIDES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84927625770     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-12-404     Document Type: Article

References (32)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29. 10.3322/caac.20138.
2. Philip PA, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol N, Emens L, O'Reilly E, Korc M, Ellis L, Benedetti J, Rothenberg M, Willett C, Tempero M, Lowy A, Abbruzzese J, Simeone D, Hingorani S, Berlin J, Tepper J: Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol 2009, 27:5660-5669. 10.1200/JCO.2009.21.9022.
3. Tan BT, Park CY, Ailles LE, Weissman IL: The cancer stem cell hypothesis: a work in progress. Lab Invest 2006, 86:1203-1207. 10.1038/labinvest.3700488.
4. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM: Identification of pancreatic cancer stem cells. Cancer Res 2007, 67:1030-1037. 10.1158/0008-5472.CAN-06-2030.
5. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C: Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1:313-323. 10.1016/j.stem.2007.06.002.
6. Li C, Wu JJ, Hynes M, Dosch J, Sarkar B, Welling TH, di Pasca Magliano M, Simeone DM: c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology 2011, 141:2218-2227. 10.1053/j.gastro.2011.08.009.
7. Kim MP, Fleming JB, Wang H, Abbruzzese JL, Choi W, Kopetz S, McConkey DJ, Evans DB, Gallick GE: ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS One 2011, 6:e20636. 10.1371/journal.pone.0020636.
8. Adikrisna R, Tanaka S, Muramatsu S, Aihara A, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Yamaoka S, Arii S: Identification of pancreatic cancer stem cells and selective toxicity of chemotherapeutic agents. Gastroenterology 2012, 143:234-e7. 10.1053/j.gastro.2012.03.054.
9. Lee HJ, You DD, Choi DW, Choi YS, Kim SJ, Won YS, Moon HJ: Significance of CD133 as a cancer stem cell markers focusing on the tumorigenicity of pancreatic cancer cell lines. J Korean Surg Soc 2011, 81:263-270. 10.412/jkss.2011.81.4.263.
10. Banerjee S, Nomura A, Sangwan V, Chugh R, Dudeja V, Vickers SM, Saluja A: CD133+ tumor initiating cells in a syngenic murine model of pancreatic cancer respond to Minnelide. Clin Cancer Res 2014, 20:2388-2399. 10.1158/1078-0432.CCR-13-2947.
11. Zhu H, Wang D, Zhang L, Xie X, Wu Y, Liu Y, Shao G, Su Z: Upregulation of autophagy by hypoxia-inducible factor-1α promotes EMT and metastatic ability of CD133+ pancreatic cancer stem-like cells during intermittent hypoxia. Oncol Rep 2014, 32:935-942.
12. Hatanaka Y, Uratani Y, Hayash KT, Omori A, Sato K, Miyamoto M, Arimatsu Y: Intracortical regionality represented by specific transcription for a novel protein, latexin. Eur J Neurosci 1994, 6:973-982. 10.1111/j.1460-9568.1994.tb00592.x.
13. Liu Q, Yu L, Gao J, Fu Q, Zhang J, Zhang P, Chen J, Zhao S: Cloning, tissue expression pattern and genomic organization of latexin, a human homologue of rat carboxypeptidase A inhibitor. Mol Biol Rep 2000, 27:241-246. 10.1023/A:1010971219806.
14. Youssef EM, Chen XQ, Higuchi E, Kondo Y, Garcia-Manero G, Lotan R, Issa JP: Hypermethylation and silencing of the putative tumor suppressor Tazarotene-induced gene 1 in human cancers. Cancer Res 2004, 64:2411-2417. 10.1158/0008-5472.CAN-03-0164.
15. Liang Y, Zant GV: Aging stem cells, latexin, and longevity. Exp Cell Res 2008, 314:1962-1972. 10.1016/j.yexcr.2008.01.032.
16. Li Y, Basang Z, Ding H, Lu Z, Ning T, Wei H, Cai H, Ke Y: Latexin expression is downregulated in human gastric carcinomas and exhibits tumor suppressor potential. BMC Cancer 2009, 11:121-121.
17. Ni QF, Tian Y, Kong LL, Lu YT, Ding WZ, Kong LB: Latexin exhibits tumor suppressor potential in hepatocellular carcinoma. Oncol Rep 2014, 31:1364-1372.
18. Liang Y, Jansen M, Aronow B, Geiger H, Van Zant G: The quantitative trait gene latexin influences the size of the hematopoietic stem cell population in mice. Nat Genet 2007, 39:178-188. 10.1038/ng1938.
19. Haan G: Latexin is a newly discovered regulator of hematopoietic stem cells. Nat Genet 2007, 39:141-142. 10.1038/ng0207-141.
20. Muthusamy V, Premi S, Soper C, Platt J, Bosenberg M: The hematopoietic stem cell regulatory gene latexin Has tumor-suppressive properties in malignant melanoma. J Invest Dermatol 2013, 133:1827-1833. 10.1038/jid.2013.48.
21. Kang MH, Reynolds CP: Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009, 15:1126-1132. 10.1158/1078-0432.CCR-08-0144.
22. Vita M, Henriksson M: The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol 2006, 16:318-330. 10.1016/j.semcancer.2006.07.015.
23. Civenni G, Malek A, Albino D, Garcia-Escudero R, Napoli S, Di Marco S, Pinton S, Sarti M, Carbone GM, Catapano CV: RNAi-mediated silencing of Myc transcription inhibits stem-like cell maintenance and tumorigenicity in prostate cancer. Cancer Res 2013, 73:6816-6827. 10.1158/0008-5472.CAN-13-0615.
24. Evan G, Litflewood T: A matter of life and cell death. Science 1998, 281:1317-1322.
25. Visvader JE, Lindeman GJ: Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008, 8:755-768. 10.1038/nrc2499.
26. Reya T, Morrison SJ, Clarke MF, Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111. 10.1038/35102167.
27. Pallarès I, Bonet R, García-Castellanos R, Ventura S, Avilés FX, Vendrell J, Gomis-Rüth FX: Structure of human carboxypeptidase A4 with its endogenous protein inhibitor, latexin. Proc Natl Acad Sci U S A 2005, 102:3978-3983. 10.1073/pnas.0500678102.
28. Van ZG, Liang Y: Natural genetic diversity as a means to uncover stem cell regulatory pathways. Ann NY Acad Sci 2009, 1176:170-177. 10.1111/j.129-6632.2009.04567.x.
29. Yip KW, Reed JC: Bcl-2 family proteins and cancer. Oncogene 2008, 27:6398-6406. 10.1038/onc.2008.307.
30. Stefan JR, Guy SS: The apoptosome: signaling platform of cell death. Nat Rev Mol Cell Biol 2007, 8:405-413. 10.1038/nrm2153.
31. Murphy MJ, Wilson A, Trumpp A: More than just proliferation: Myc function in stem cells. Trends Cell Biol 2005, 15:128-137. 10.1016/j.tcb.2005.01.008.
32. Wang J, Wang H, Li Z, Wu Q, Lathia JD, McLendon RE, Hjelmeland AB, Rich JN: c-Myc is required for maintenance of glioma cancer stem cells. Plos One 2008, 3:e3769-e3769. 10.1371/journal.pone.0003769.